AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Rosiglitazone (Avandia) could increase the risk of MI by 43 per cent in patients with type-2 diabetes, US scientists claim.
The findings come from a meta-analysis of 42 trials, involving almost 18,000 patients aged an average of 56 years.
It also showed that the risk of death from all cardiovascular causes was 63 per cent higher in patients given rosiglitazone, compared with those given drug regimens excluding rosiglitazone.
Until more precise estimates of the risks of this treatment on …